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Diagnosis and treatment of schizotypal personality disorder:
evidence from a systematic review
Sophie K. Kirchner1, Astrid Roeh1, Jana Nolden1 and Alkomiet Hasan1
The main objective of this review was to evaluate studies on the diagnosis, treatment, and course of schizotypal personality
disorder and to provide a clinical guidance on the basis of that evaluation. A systematic search in the PubMed/MEDLINE databases
was conducted. Two independent reviewers extracted and assessed the quality of the data. A total of 54 studies were eligible for
inclusion: 18 were on diagnostic instruments; 22, on pharmacological treatment; 3, on psychotherapy; and 13, on the longitudinal
course of the disease. We identiﬁed several suitable and reliable questionnaires for screening (PDQ-4+ and SPQ) and diagnosing
(SIDP, SIDP-R, and SCID-II) schizotypal personality disorder. Second-generation antipsychotics (mainly risperidone) were the most
often studied drug class and were described as beneﬁcial. Studies on the longitudinal course described a moderate remission rate
and possible conversion rates to other schizophrenia spectrum disorders. Because of the heterogeneity of the studies and the small
sample sizes, it is not yet possible to make evidence-based recommendations for treatment. This is a systematic evaluation of
diagnostic instruments and treatment studies in schizotypal personality disorder. We conclude that there is currently only limited
evidence on which to base treatment decisions in this disorder. Larger interventional trials are needed to provide the data for
evidence-based recommendations.
npj Schizophrenia  (2018) 4:20 ; doi:10.1038/s41537-018-0062-8
INTRODUCTION
Schizotypy is a heterogenous syndrome that is expressed across
multiple dimensions, including cognitive-perceptual, disorganized,
and interpersonal symptoms1 or according to the symptomology
of schizophrenia, positive, negative, and disorganized factors.2–4
Raine1 described two types of schizotypy: (1) neurodevelopmental
schizotypy with relatively stable traits and signiﬁcant brain and
neurocognitive impairments that predispose to schizophrenia, and
(2) pseudoschizotypy, a pronounced psychosocial entity with
more symptom ﬂuctuation that is unrelated to schizophrenia.
Schizotypy, as a broader collection of both clinical and nonclinical
traits, is assessed by psychometric inventories such as the
Wisconsin Scales of Schizotypy.3 The assessments for schizotypal
traits are mainly used to deﬁne a high-risk group and its
proneness to psychosis.5 Mason described 16 different schizotypy
scales that were based on clinical concepts or deﬁnitions and six
scales for psychometric/personality measures of schizotypy.5
According to the theoretical models of Meehl,6,7 Lenzenweger,8
Chapman,9 and Kwapil,10 schizotypy is a premorbid condition. The
term schizotypy refers to both people with schizotypal personality
disorder (STPD) and healthy individuals in the general population
with certain personality traits and a latent liability for psychosis.1
Consequently, research has been performed in both clinical
patients and healthy schizotypal individuals. Several authors argue
for a dimensional approach and a continuum between schizotypal
traits and schizophrenia spectrum disorder1,11,12; support for their
argument is provided by genetic and linkage studies showing a
considerable overlap between genetic association proﬁles in
schizotypy and schizophrenia.13,14
Since the introduction of the diagnosis of STPD in Diagnostic
and Statistical Manual of Mental Disorders, Third Edition (DSM-III)
in 1980, the diagnosis and treatment of STPD have remained
difﬁcult because of the lack of evidence-based algorithms. The
original STPD item set was derived from the criteria of borderline
schizophrenia seen in the relatives of schizophrenia patients. The
differentiation between schizotypal traits and STPD is clinically
important and reﬂects the degree of impairment in occupational
and interpersonal functioning and the severity of symptom
presentation.14 This review focuses on the diagnosis of and
therapeutic approaches in patients with a disease severity that
fulﬁlls the criteria of STPD not only as a premorbid condition or
risk state but also as a separate diagnostic entity.
For years, the International Classiﬁcation of Diseases (ICD) from
the World Health Organization (WHO) and other classiﬁcation
instruments, e.g., the DSM from the American Psychiatric
Association (APA), have differed in their classiﬁcation of STPD
(referred to as schizotypal disorder in the ICD): In ICD-9 and -10, it is
listed under schizophrenia spectrum disorders, whereas in DSM-III
to -5 it is classiﬁed as a personality disorder. In the forthcoming
ICD-11, it will remain in the block of schizophrenia spectrum
disorders.15 In DSM-5, a diagnosis of STPD is deﬁned by the
following symptom categories: (1) general impairments in
personality and self-functioning (identity and self-direction) and
in interpersonal functioning (empathy, intimacy); (2) STPD-speciﬁc
pathological personality traits, described as psychoticism, eccen-
tricity, cognitive and perceptual dysregulation, and unusual beliefs
and experiences, (3) detachment characterized by restricted
affectivity and withdrawal, and (4) negative affectivity character-
ized by suspiciousness. In ICD-10,16 and very likely in ICD-11,
however, schizotypal disorder (F21) is characterized by eccentric
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behavior and changes in thinking and affect similar to those in
schizophrenia; the evolution and course of the disease resemble
those of a personality disorder (PD).
The prevalence of STPD has been described as ranging from
0.6% in a Norwegian sample to 4.6% in an American sample.17
Men (4.2%) are more often affected than women (3.7%).17
Common differential diagnoses are other PDs such as the
borderline personality disorder (BPD), attention-deﬁcit disorder
(inattentive type), social anxiety disorder, autism-spectrum dis-
order, and dysthymia.18 Comorbidities can complicate the disease
course and treatment responses, and several studies focus on
interventions for patients with comorbid obsessive-compulsive
disorder (OCD)19 and BPD. Schizotypy occurs more often in
relatives of patients with schizophrenia or a Cluster A PD. Twin
studies showed highly stable genetic factors and rather transient
environmental factors for an increased risk for the schizotypal
syndrome,20 and genetic risk variants for schizophrenia could also
be linked to STPD.21–23 The conversion rates from STPD to
schizophrenia spectrum disorders vary between 20 and >40%,
depending on the follow-up interval.1,24 Imaging studies detected
numerous group-level differences in the size of speciﬁc brain
regions in individuals with STPD or schizotypy in comparison with
healthy participants, patients with schizophrenia, and patients
with other PDs.18
Despite these research efforts, evidence-based recommenda-
tions are still lacking for the diagnosis and treatment of STPD.
National and international treatment guidelines for schizophrenia
spectrum disorders (e.g., from the APA, the National Institute for
Health and Care Excellence and World Federation of Societies of
Biological Psychiatry (WFSBP)) do not discuss this topic, and
speciﬁc guidelines for personality disorders pay only little
attention to STPD.25 Rosell et al.18 recently published a non-
systematic literature review on the epidemiology, functional
impairment, heritability and genetics, cognitive impairments,
social-affective disturbances, and neurobiology of STPD. This
detailed review provides a deeper insight into the pathophysiol-
ogy of and experimental research on STPD and includes
information on imaging and genetic and psychological testing.18
Nevertheless, it remains unclear which diagnostic tools, medica-
tion, or psychotherapy are recommended. Therefore, the main
objective of this systematic review, which was based in principle
on the recommendation of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses group,26 was to evaluate
the literature on the diagnosis and treatment of patients seeking
help for STPD. In addition, it offers some information on the
longitudinal course of STPD and conversion rates to other
schizophrenia spectrum disorders.
RESULTS
Articles on diagnostic instruments
Study characteristics. When examining the articles on diagnostic
instruments, we focused on studies that tested disease criteria27–
31 and clinical diagnostic questionnaires for STPD.32–39 One study
did not speciﬁcally evaluate a diagnostic questionnaire but
compared a factor analysis model with established
questionnaires.40
Individual outcomes. Five studies aimed at evaluating the
variables of the diagnostic criteria, the shifts in diagnosis from
DSM-III to -5 or ICD-8 to -10 and their effect on diagnostic
sensitivity, speciﬁcity, and diagnostic overlap,27,28,30,31,41 as indi-
cated in Table 1. The reliability of the DSM-III criteria had an
adequate mean kappa of 0.71.27 In DSM-III, the diagnoses of BPD
and STPD interacted on the symptom level.27 In DSM-III-R, the
threshold for an STPD diagnosis was raised, and the number of
STPD diagnoses consequently decreased by 40%. This offered a
sharper discrimination between STPD and related PDs, such as
BPD and schizoid PD.30 In the evolution of the ICD system, the
threshold for meeting symptom criteria was also crucial for
differential diagnosis: Whereas in ICD-8/-9 less patients would
have been diagnosed with STPD, in ICD-10 the threshold was
lowered and more patients were diagnosed with STPD. In the ICD
system, the severity of the disease may mark the discrimination
between STPD and schizophrenia, which would favor a dimen-
sional diagnosis concept.31 Most of the studies evaluated the
inter-rater reliability (which ranged from 0.62 to 0.91) and
test–retest reliabilities (which ranged from 0.64 to 0.84) of the
diagnostic instruments; reliabilities were adequate (see Table 1).
Among the diagnostic instruments, three were identiﬁed as being
suitable for diagnosis because they had adequate reliabilities and
validities for the respective diagnostic criteria: the Structured
Interview for DSM-III Personality Disorder (SIDP),33 the Semi-
structured Interview for DSM-III-R Personality Disorders (SIDP-R),35
and the Structured Clinical Interview for DSM-IV (SCID-II)37 (see
Table 1). The self-report instruments Schizotypal Personality
Questionnaire (SPQ) and Schizotypal Personality Questionnaire—
Brief (SPQ-B) were designed as screening instruments for STPD.
The SPQ-B shows adequate internal consistency (coefﬁcient
kappa= 0.87),42 and the SPQ shows strong correlations between
patients’ responses and SCID-II–rated symptoms.38,43 The Person-
ality Diagnostic Questionnaire-4+ (PDQ-4+) is also a self-report
instrument for diagnosing PD. It has more false-positive results
than the SCID-II and is therefore only useful as a screening tool for
PDs but not as a diagnostic tool.44 The Minnesota Multiphasic
Personality Inventory (MMPI) could not differentiate between
individuals with STPD and schizophrenia.45 However, a distinct
proﬁle (MMPI 2-7-8) showed an enrichment of diagnoses of
Cluster A PDs when compared with SIDP-IV interviews. None of
the instruments was designed to evaluate disease severity. Three
studies compared diagnostic interviews with factor analysis
models.35,40,44 According to Battaglia et al.35, the three factors
cognitive-perceptual, interpersonal, and oddness best describe
the diagnosis of STPD; Fossati et al.37 made the same statement,
but these two studies had overlapping patient cohorts. Sanislow
et al.40 developed a four-factor model and argued that it was
signiﬁcantly better than the established unitary “generic” model.40
Please see Table 1 for details.
Articles on interventional drug treatment trials
Study characteristics. Most of the studies were prospective
double-blind, placebo-controlled trials,46–56 and all publications
reported single-center results. We also identiﬁed one double-
blind, treatment-controlled trial;57 one single-blind, placebo-
controlled trial;58 four open-label trials;59–62 one retrospective
study;63 and four case reports.64–67 Please see Table 2A, B and
Supplementary Table 3 and 4 for further study details and level of
evidence (LoE) grading. In total, 16 individual drug treatments
were studied. The most frequently studied drug was risper-
idone,50,53,54,62 and the most frequently studied class of drugs
were the antipsychotics,47,48,50,53,54,57–60,62,63,66 followed by the
antidepressants.46,61,64,65 Six studies tested other neuroactive
drugs.49,51,52,55,56,67 In most studies, the main outcome measure-
ment was a general psychiatric symptom scale, such as the Brief
Psychiatric Rating Scale,60,63,67 the Hopkins Symptom Check-
list,48,61 and the Psychiatric Assessment Interview.57 Three trials
used interviews for speciﬁc psychotic symptoms, such as the
Positive and Negative Symptom Scale (PANSS).50,53,56 Some
studies focused on patients with comorbidities of OCD or BPD
and consequently measured outcome with the Yale-Brown
Obsessive Compulsive Scale (YBOCS)46,48,59,66 or the Self-
Injurious Behavior scale.47 One study used a speciﬁc tool, the
SPQ, to assess the severity of STPD as an additional outcome
measurement tool.50 Common secondary outcome tools were
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measurements for global functioning, i.e., the Global Assessment
of Symptoms60 and Clinical Global Impression,50 or for depressive
symptoms, i.e., the Hamilton Rating Scale for Depression.46,50,62 Six
studies had cognitive measures, i.e., working memory,49,52,55
context processing,51 reaction time,54 response inhibition,54 or a
combination of different cognitive categories,53 as a primary or
secondary outcome.
Individual outcomes. Most of the studies on an antipsychotic
drug intervention found a positive effect in STPD (see Table 2A).
Thiothixine reduced general symptoms (especially illusions, ideas
of reference, paranoid ideation, cognitive deﬁcits, and anxiety) in
cohorts of mixed BPD and STPD patients, but the respective
studies found no signiﬁcant relationship between diagnosis and
outcome of treatment.47,57 Risperidone was the only drug that was
evaluated in studies that fulﬁlled relevant study quality criteria,
such as reporting effect sizes, being randomized, and using
quantitative measures and standardized questionnaires. It was
evaluated in four independent studies: Koenigsberg et al. showed
a reduction in the PANSS score in STPD but no difference in the
STPD-speciﬁc SPQ;50 Rabella et al. reported an improvement in
reaction time after treatment with risperidone;54 McClure et al.
found no beneﬁcial effect of risperidone in either the PANSS or
cognitive measurements;53 and the open-label study by Ryba-
kowski et al. found an increase in social and occupational
functioning and cognitive tests after risperidone treatment.62 In
an open-label augmentation trial, a small cohort (n= 11) of
patients with STPD had signiﬁcant improvements in psychosis and
depression ratings when treated with olanzapine.60 In an open-
label study in patients with comorbid OCD and STPD, a
combination of ﬂuvoxamine and olanzapine showed beneﬁcial
effects, i.e., it reduced the YBOCS score,59 and the concomitant
diagnosis of STPD was signiﬁcantly associated with a positive
response. In a retrospective study, Di Lorenzo et al. reported a
decrease of general symptoms when patients with schizophrenia
spectrum disorder were treated with aripiprazole; patients with
STPD were included, but no speciﬁc results were mentioned.63 In
one case report, clozapine treatment reduced symptoms in a
patient with comorbid OCD and STPD.66 Three studies investigat-
ing the use of antipsychotics analyzed mixed cohorts of STPD and
BPD patients,47,48,57 and one study analyzed patients with
schizophrenia spectrum disorder.63
Studies evaluating antidepressant treatment examined only
mixed (BPD and STPD) or comorbid (OCD and STPD) cohorts (see
Table 2B). In an open-label trial of ﬂuoxetine, Markovitz et al.
measured a reduction of general symptoms in patients with BPD,
STPD, or both,61 regardless of the diagnosis. In another study,
clomipramine showed no signiﬁcant effects on OCD symptoms in
a cohort of patients with OCD and STPD, and the authors reported
a worse treatment outcome in patients with comorbid STPD than
in those with other PD diagnoses.46 One case report described a
patient with STPD who developed psychotic symptoms after
treatment with ﬂuoxetine,64 and other case reports showed
positive effects of clomipramine, paroxetine, and buspirone on
depressive or OCD symptoms46,65 (see Supplementary Tables 3C
and D). Five studies tested other substances and their effect on
cognitive impairments in patients with STPD (see Supplementary
Table 3): On the basis of studies showing positive results of
catecholamine agonistic treatment in schizophrenia-related dis-
orders, Siegel et al. tested d-amphetamine in a cohort of patients
with STPD and found an improvement in the Wisconsin Card
Sorting Test (WCST); however, the authors found no effect of
symptom change on the PANSS score.56 Two studies tested
dopamine agonists (pergolide and dihydrexidine) and showed
improvements in working and verbal memory, executive function-
ing, information processing, and divided attention.52,55 Two
studies tested modulators of the autonomous nervous system
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enhancer of the parasympathetic nervous system, and guanfacine,
an α2A receptor agonist and sympatholytic drug) and their effect
on cognition. These studies showed improvements in verbal
memory, visuospatial working memory, and context proces-
sing.49,51 The sizes of the studies varied between 1 patient with
STPD in a larger mixed cohort63 and up to 31 patients with STPD53
(see Supplementary Table 2).
Articles on psychotherapy
Study characteristics. We identiﬁed one randomized clinical trial
that compared integrated therapy with standard treatment,68 one
uncontrolled clinical trial,69 and one case report of a patient with
OCD and comorbid STPD.70 The sizes of the studies varied from
170 to 7968 patients with a diagnosis of STPD (see Supplementary
Table 2).
Individual outcomes. An uncontrolled prospective trial of a
psychodynamic day-care treatment program found no beneﬁt
for STPD patients.69 One case report showed a reduction of
symptoms in a patient with STPD and OCD70 after social skills
training. Another trial also reported a positive effect of social skills
training, i.e., STPD patients with this training had a lower transition
rate from STPD to a psychotic disorder.68 We found no trial that
evaluated cognitive behavioral therapy in STPD (see Table 3).
Articles on longitudinal course and follow-up studies
Study characteristics. We included eight studies of clinical
cohorts.71–78 Studies with mixed clinical and non-clinical cohorts
were included if they predicted the development of an STPD
diagnosis from childhood to adulthood or the conversion rate to
psychotic illness.79–81 One article focused of the stability of a
diagnosis of STPD in young adult twins.20 The study size
depended on the investigated cohort (for details see Supplemen-
tary Table 2).
Individual outcomes. The follow-up periods of the studies ranged
from a minimum of 1 year81 to 27 years.80 In a mixed cohort of
healthy and mentally ill children, Bernstein et al. showed that an
early STPD diagnosis during adolescence rarely persisted over a 2-
year follow-up period.79 Along the same lines, in their study in
adults Grilo et al. reported a remission of the STPD diagnosis in
61% of patients and suggested that, although maladaptive traits
may persist, the severity of symptoms can change.76 In contrast,
Asarnow et al. showed that children with a diagnosis of STPD
mostly kept the diagnosis, but 25% of them developed more
severe schizophrenia spectrum disorders (schizophrenia or
schizoaffective disorder).81 Olin et al. evaluated the relationship
between personality traits and disorders in a community-based
cohort of healthy and mentally ill children and concluded that
early traits can be predictive for the development of an STPD. Four
studies evaluated longitudinal global functioning and impair-
ment:71–74 Impairments in global functioning and social impair-
ment differed depending on the study sample, but, overall,
patients with pure STPD had less impairment than patients with
other comorbid PDs or SZ. In particular, patients with comorbid
BPD had poor global functioning. Treatment with antipsychotic
medication was common in STPD patients.74,75 They were also
frequently hospitalized and received psychotherapy.75 Two
studies evaluated the stability of symptoms over time: McGlashan
et al. found paranoid ideation and unusual experiences to be the
most stable, whereas oddness appeared to be the least prevalent
and most changeable;78 and Kendler et al. studied the stability of
Cluster A PDs in twins and concluded that genetic risk factors lead
to highly stable subtypes of the disorder, whereas shared
environmental risk factors lead to rather transient symptoms20
(see Table 4). Two studies focused on the conversion from STPD to
a psychotic illness and found rates of 25–48%.24,82
Quality of the studies
The composition and size of the cohorts varied greatly across the
studies, and all treatment studies were single center. Some studies
in mixed samples of patients reported results on very few or only
single STPD patients. It remains questionable whether the results
of these studies can be applied to a larger group of patients with
STPD. Most of the articles did not mention disease severity
because of a lack of a suitable measurement tool. A variety of
methods for evaluating the quality of diagnostic instruments, the
outcome of clinical interventional studies (drug treatment or
psychotherapy), or longitudinal outcome were applied across the
studies, resulting in a high heterogeneity and hampering
comparability.
DISCUSSION
We present a systematic review of diagnostic instruments and
pharmacological and psychosocial treatment strategies for STPD.
After performing a standardized and systematic literature search
and analysis, we assessed 94 full-text articles for eligibility and
evaluated 54 of them. At this point, it would be premature to
make clear recommendations for the use of speciﬁc diagnostic
instruments or drug or psychotherapy treatment approaches. Our
evaluation of diagnostic instruments made clear that the
diagnosis of STPD has changed over time. In each diagnostic
system, the threshold for meeting symptom criteria seems to
differentiate between related diseases, such as other PDs or
schizophrenia. Nearly all the diagnostic instruments discussed for
STPD have adequate inter-rater and test–retest reliability. Our
review conﬁrms that the SIDP for DSM-III, SIDP-R for DSM-III-R, and
SCID-II for DSM-IV are suitable for diagnosing STPD, but we found
that the diagnostic tool PDQ-4+ is more suitable for screening.
Factor analysis models are frequently discussed as a diagnostic
alternative to catalogs with rather arbitrary diagnostic criteria. A
complete review of the scales used to access schizotypy as a
broad concept can be found in the review by Mason, which
focuses not only on the clinical diagnosis but also on psycho-
metric measurements that assess schizotypal personality traits and
deﬁne a high-risk group for schizophrenia.5 Longitudinal studies
examined the stability of the diagnostic entity and observed
moderate-to-high remission rates between an early childhood
onset and later adulthood. Patients suffering of comorbid BPD
showed poorer social functioning than patients with pure
STPD.71,72 Yet, drug treatment responses in patients with
comorbid BPD were regardless of the diagnosis.47,57,61 Patients
suffering of a comorbid OCD showed better response rates after
treatment with olanzapine59 and poorer responses after clomi-
pramine treatment.46 The articles on treatment clearly showed
that antipsychotics are the most frequently used drugs. When we
considered only studies that were of acceptable methodological
quality (see LoEs in Tables 2 and 3 and Supplementary Table 3 and
4), risperidone had the best, but still limited, evidence for reducing
clinical symptoms in patients with STPD. Antidepressants have
only been tested in mixed cohorts (patients with comorbid OCD or
BPD), making it difﬁcult to draw deﬁnite conclusions on their
effectiveness in STPD. Most of the drug treatment studies were
conducted in patients with STPD and a comorbid disorder, which
also limits our ability to draw conclusions. Moreover, some studies
included only a few patients, resulting in an LoE of 2− to 3.
Remarkably, to the best of our knowledge no treatment guidelines
or Cochrane Collaboration reviews exist that provide a compre-
hensive discussion of treatment alternatives for STPD. The WFSBP
Guidelines for Biological Treatment of Personality Disorders
provide only general recommendations for antipsychotics on the
basis of minimal evidence from clinical trials and expert opinion
(Herpertz et al. 2007).
Diagnosis and treatment of schizotypal personality disorder:. . .
SK Kirchner et al.
7





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diagnosis and treatment of schizotypal personality disorder:. . .
SK Kirchner et al.
8





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diagnosis and treatment of schizotypal personality disorder:. . .
SK Kirchner et al.
9




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diagnosis and treatment of schizotypal personality disorder:. . .
SK Kirchner et al.
10




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diagnosis and treatment of schizotypal personality disorder:. . .
SK Kirchner et al.
11

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diagnosis and treatment of schizotypal personality disorder:. . .
SK Kirchner et al.
12
npj Schizophrenia (2018)  20 Published in partnership with the Schizophrenia International Research Society
Table 3. Qualitative synthesis of psychotherapy
Reference Study
population





























per week), art therapy
groups (2× per week), body






patients was measured by
the change in symptoms
(measured by General






(change in GSI: 0.77 ± 0.50,
change in HSRS: 8.9 ± 6.9, p
< 0.01) improved the most,
followed by the BPD and
OCD groups, the
improvement for patients
with STPD was not
statistically signiﬁcant
(change in GSI: 0.40 ± 0.77,
change in HSRS: 0.2 ± 7.1).
No patients committed
suicide. One STPD patient
made a suicidal attempt
and was temporarily
transferred to the acute
ward. One STPD patient





















of OCD by DSM-
III-R criteria
No criteria Social skills training plus
exposure with response
prevention (ERP)
The patient showed a
decrease in OCD
symptomatology as
assessed by the YBOCS, as
well as decreases in
depression and anxiety as
assessed by the Hamilton
Rating Scale for Depression
and the Hamilton Rating
Scale for Anxiety. This is
consistent with the
hypothesis that OCD, when
presented with comorbid
schizotypal personality, is





























In the multivariate model,
male gender increased risk























aThe descriptions of outcome are direct citations or extracts from the referred publications
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Table 4. Qualitative synthesis of longitudinal outcome studies of patients with schizotypal personality disorder
Reference Study population Follow-up period Outcomea
Plakun et al.71 ntotal= 237 psychiatric patients,
nSTPD= 13, nSTPD+BPD= 6
14 years Diagnoses in this study were based on DSM-III criteria. Patients suffering
from STPD without comorbid major affective disorder functioned better
than patients with SZ. They had higher scores in global functioning
(GAS) than SZ patients at baseline but not at follow-up. STPD patients
with comorbid BPD were as impaired as schizophrenics at admission but
signiﬁcantly better at follow-up
McGlashan72 ntotal= 253 psychiatric patients,
nSTPD= 10, nSTPD+SZ= 61, nSTPD
+SZ+BPD= 30, nSTPD+BPD= 18
Range: 2–32 years STPD as deﬁned by DSM-III criteria appeared to be common in the
Chestnut Lodge follow-up study patients, although it was rare as a pure
syndrome. From the perspective of follow-up, STPD seemed to be
related to SZ but not to BPD. The mixed Axis II borderline syndrome
(STPD+BPD) had a long-term proﬁle closer to BPD than to STPD. The
cohorts meeting STPD criteria had relatively poor social adjustments
and fewer social contacts. The pure STPD cohort achieved the highest
level on education compared to the mixed diagnoses. The pure STPD
sample was mainly single (70%) and male (60%). Premorbid functioning
was poor socially and good instrumentally
Modestin et al.73 ntotal= 39 psychiatric patients,
nSTPD= 14 (7 for follow-up), nSZ
= 25 (17 for follow-up)
4 years Diagnosis of STPD was based on DSM-III, of SZ on ICD-9 and parts on
DSM-III. A relationship not only between STPD and SZ but also between
STPD and BPD could be detected. Pure STPD patients are rarely
dysfunctional and less likely to require hospital care. Therefore, the
clinical sample investigated is small and might not be representative for
all STPD patients. On a blind examination, STPD patients in this cohort
were found to be less socially adjusted and they tended to be more
symptomatic. Compared with a small DSM-III schizophrenia subgroup,
STPD patients undertook more suicide attempts. STPD patients were
rating higher in social dissatisfaction. Patients with STPD were more
anxious and they tended to suffer more from obsessive-compulsive
symptoms and depression. Transient psychoses were frequent in STPD
patients. The average neuroleptics dose was twice as low in STPD
compared to SZ (92% of ntotal received neuroleptic medication)
Mehlum et al.74 ntotal= 97 patients with PD, nSTPD
= 13 at admission, nSTPD= 9 at
discharge
range: 1.6–4.9 years STPD diagnoses were made according to DSM-III-R at index
hospitalization and by SCID interview at follow-up. STPD patients
displayed a moderate symptom reduction after 3 years of treatment but
retained relatively poor global functioning. They were least socially
adjusted, employed, and self-supporting of all diagnostic subgroups.
STPD and BPD patients had far more inpatient treatment than other PDs
Bernstein et al.79 ntotal= 733 community-based
adolescents
2 years The overall prevalence of personality disorders peaked at age 12 years in
boys and at age 13 years in girls and declined thereafter. STPD was the
least prevalent Axis II disorder (moderate STPD 1.8%, severe STPD 1.2%).
Children who met the criteria for STPD had increased social
impairments, school or work problems, and a higher comorbidity with
Axis I disorders. Longitudinal follow-up revealed that most Axis II
disorders did not persist over a 2-year period. Subjects with disorders
identiﬁed earlier remained at elevated risk for receiving a diagnosis
again at follow-up (persistence after 2 years: for moderate STPD 9%, for
severe STPD 11%)





The lifetime diagnoses used in the study are based on DSM-III-R. The ﬁrst
assessment was at age 15 years, the second at age 25 years, and the
third between age 39 and 42 years. Those who later developed STPD
were found to be more passive and unengaged and more
hypersensitive to criticisms compared with the non-schizophrenia
groups according to school reports. Males who developed STPD were
found to be less disruptive and hyper-excitable compared with males
with schizophrenia; females with STPD did not differ from females with
schizophrenia. A receiver operating characteristic analysis found these
factors to predict 73.5% of future STPDs. The three major factors
accounting for 54.4% of the variance were labeled as “socially anxious
and withdrawn,” “disruptive and hyper-excitable,” and “passive and
unengaged.” These ﬁndings suggest that pre-schizotypal traits may be
identiﬁed in late childhood or adolescence
Comparative groups: ncomp1= 31
SZ children, ncomp2= 37
nonpsychotic but mentally ill
children, ncomp3= 68 children not
mentally ill but schizophrenic
mother, ncomp4= 60 healthy
children
Grilo et al.76 ntotal= 633 patients, nPD= 544,
nMDD= 89, nSTPD= 78
2 years The study examined the stability of different personality disorders over
time. The STPD remission rate was 61% after 24 months. Remission rates
after a more stringent deﬁnition with two or fewer criteria (by the
DSM–IV Personality Disorders Follow Along Version, DIPD-FAV) after 12
consecutive months was 23% for STPD. Dimensionally, these ﬁndings
suggest that PDs may be characterized by maladaptive trait
constellations that are stable in their structure (individual differences)
but can change in severity or expression over time
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In summary, our systematic review shows that the best
evidence for efﬁcacy in STPD is available for risperidone and to
a limited extent for olanzapine. The literature on psychotherapy is
sparse and does not allow us to make any recommendations,
although social skills training seems to be effective and should be
offered to patients with STPD. Large-scale naturalistic and
interventional trials with deﬁned diagnostic cohorts and strict




This systematic review was conducted by searching the PubMed/
MEDLINE databases for papers published at any time. We
conducted the ﬁnal search on September 14, 2016, at which time
the data source contained studies from April 1, 1947, to August 21,
2016. A total of 145 combinations of search terms were used to
search the databases with the ENDNOTE X7 search tools (see
Supplementary Information). Duplicates were removed by using
the ENDNOTE X7 duplication detection feature. The publications
(titles and abstracts) were then screened for relevance. To be
included, the articles had to report on studies of original data and
focus on the diagnosis, treatment, or follow-up of patients with
STPD. Because including only studies with a Scottish Intercollegi-
ate Guidelines Network (SIGN) LoE of 1− to 1++ would have
limited the number of studies available for inclusion, we included
not only randomized control trials but also cohort studies,
retrospective non-analytical studies, and case studies (LoE 2++
to 3). Expert opinions (LoE 4) were not considered. Study designs
and LoE grading are described in the Tables 2A, B, and 3, and
Supplementary Tables 3 and 4. Reviews, meta-analyses, and non-
English publications were excluded. Two reviewers independently
analyzed the full-text publications and retrieved data on clinical
diagnosis and treatment. We searched also three additional
databases (WHO Clinical Trials (http://apps.who.int/trialsearch/),
ClinicalTrials (https://clinicaltrials.gov/), and the Cochrane Library
(http://www.cochranelibrary.com/)) for ongoing or planned clinical
trials and for systematic reviews or meta-analyses. Using the
search term “schizotypal personality disorder,” we identiﬁed 18
Table 4 continued
Reference Study population Follow-up period Outcomea
Warner et al.77 ntotal= 376 patients with PD 2 years This study explores the extent to which relevant personality traits are
stable in individuals diagnosed with four personality disorders
(schizotypal, borderline, avoidant, and obsessive-compulsive personality
disorders). The PDQ-IV was used for screening. The DIPD-IV was used for
making the initial diagnosis based on DSM-IV criteria. The test–retest
kappa for STPD was 0.64. There was an insufﬁcient sample size in the
inter-rater reliability sample to calculate the kappa for STPD, but
diagnostic agreement was 100%. Participants were interviewed at
6 months, 1 year, and 2 years following the baseline assessment.
Changes in personality traits were determined via a re-administration of
the NEO–PI–R at the 1- and 2-year follow-up. The DIPD–IV was modiﬁed
to record the presence of each criterion for the four PDs for each month
of the follow-up interval. The standardized parameter estimates
reﬂecting the stability for the latent trait variable across time were
signiﬁcant and quite large (β= 0.76 and β= 0.83, both ps < 0.01) as were
the stability estimates for STPD (β= 0.90 and β= 0.81, both ps < 0.01).
The results demonstrate signiﬁcant cross-lagged relationships between
trait change and later disorder change for three of the four personality
disorders studied
Asarnow et al.81 nSTPD= 12 children, nSZ= 18
children
range: 1–7 years There was signiﬁcant continuity between SZ spectrum disorders in
childhood and adolescence. The most common clinical outcome for
children with STPD was continuing STPD, supporting the hypothesis of
continuity between childhood and later STPD. However, 25% of the
STPD sample developed more severe SZ spectrum disorders
(schizophrenia or schizoaffective disorder, also supporting the
hypothesis that STPD represents a risk or precursor state for more severe
SZ spectrum disorders
McGlashan et al.78 ntotal= 474 patients with
personality disorders, nSTPD= 85
2 years In this study, a 24-month follow-up was obtained to evaluate the change
of personality disorder criteria over time. For STPD, the most prevalent
and least changeable criteria over 2 years were paranoid ideation, and
unusual experiences. The least prevalent and most changeable criteria
were odd behavior and constricted affect
Woods et al.82 n= 377 patients with prodromal
syndrome, nHSC= 196, nFHR= 40,
NSTPD=49
2.5 years 40% of prodromal patients converted to fully psychotic illness during 2.5
years of follow-up. Corresponding rates for help-seeking comparison
(HSC) group, familial high-risk (FHR) group, and STPD subjects were
correspondingly 4, 0, and 36%. Cox regression comparing distinguished
prodromal patients from HSC but not from STPD subjects
Debbane et al.24 n= 376 patients by a clinically
relevant expression of schizotypy
(i.e., STPD, schizoid PD, or SD
range: 2–20 years The conversion rates from STPD to a psychotic disorder varied between
25% and 48%. Suspected STPD in children, however, seldom led to the
later emergence of a schizophrenic-spectrum psychotic disorder (only
6.25%)
Kendler et al.20 ntotal= 2282 twins range: 6–11 years The study examines the stability of genetic and environmental factors in
paranoid and schizotypal PD. The stability over time of the criteria
counts for STPD, estimated as polychoric correlations, was +0.40. 71% of
the temporal stability derived from the effect of genetic factors. Shared
genetic risk factors for two of the Cluster A PDs are highly stable in
adults over a 10-year period while environmental risk factors are
relatively transient. Over two thirds of the long-term stability of the
common Cluster A PD liability can be attributed to genetic inﬂuences
aThe descriptions of outcome are direct citations or extracts from the referred publications
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clinical trials. Furthermore, we found two additional trials that had
been completed; however, upon closer inspection it became clear
that they did not meet the inclusion criteria for this systematic
review. We identiﬁed one protocol83 in the Cochrane Library, but it
was withdrawn with no results in 2014.
Our search strategy yielded 3420 unique studies, 3326 of which
were excluded after we had screened the titles, abstracts, and
article format reviews, resulting in 94 full-text articles. These 94
articles were scanned for the inclusion criteria of this systematic
review—to be included, studies had to investigate diagnostic
instruments for or the treatment or longitudinal course of STPD.
After full-text screening, 38 articles had to be excluded because
they did not include original data or were not about clinical
patients with STPD. The remaining 56 articles were sorted into the
following categories: clinical diagnostic instruments (18 studies),
pharmacological treatment (22 studies), psychotherapy (3 studies),
and longitudinal course and follow-up (13 studies) (see Supple-
mentary Information). Publications on diagnostic questionnaires
were only included if they evaluated diagnostic criteria or
questionnaires as assessment tools. Articles on factor analysis
models alone were excluded, and publications on drug treatment
were excluded if there was no report of a clinical outcome. We
identiﬁed three overlapping patient cohorts: one in the articles on
diagnostic instruments (Battaglia et al.35 and Fossati et al.44); one
in the articles on drug treatment (Goldberg et al. 198647 and
198748); and one in the Chestnut Lodge cohort (McGlashan et al.
published an article on testing DSM-III criteria29 and a 2-year
follow-up study in a separate article72).
General study characteristics
We assumed a large heterogeneity in disease severity among the
included patients who were recruited in outpatient and inpatient
settings. Because of the inconsistent outcome measures in the
interventional groups, in our view the available data were not
suited to perform quantitative analyses, e.g., with a meta-
analytical approach. Some study populations included also
healthy and population-based individuals, but these studies were
only taken into consideration when a clinical diagnosis of STPD
was mentioned.20,34,36,38,79,80 Most of the studies focused on
adults, although three focused on children and the longitudinal
course of their diseases.79–81 The study sizes varied greatly, as
indicated in Supplementary Table 2.
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